NASDAQ:ZBIO Zenas BioPharma Q3 2025 Earnings Report $30.81 -0.44 (-1.41%) As of 02:25 PM Eastern ProfileEarnings HistoryForecast Zenas BioPharma EPS ResultsActual EPS-$1.22Consensus EPS -$0.87Beat/MissMissed by -$0.35One Year Ago EPSN/AZenas BioPharma Revenue ResultsActual RevenueN/AExpected Revenue$10.00 millionBeat/MissN/AYoY Revenue GrowthN/AZenas BioPharma Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Zenas BioPharma Earnings HeadlinesHC Wainwright Forecasts Higher Earnings for Zenas BioPharmaAugust 20 at 1:29 AM | americanbankingnews.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 18 at 4:15 PM | globenewswire.comSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing total outflows to 14 billion. At the same time, the World Gold Council recorded the highest quarterly central bank gold buying on record, with buyers taking physical delivery instead of paper shares.August 20 at 1:00 AM | Behind the Markets (Ad)Zenas BioPharma's (ZBIO) "Buy" Rating Reiterated at GuggenheimAugust 17 at 1:18 AM | americanbankingnews.comZenas BioPharma's (ZBIO) "Outperform" Rating Reiterated at WedbushAugust 17 at 1:18 AM | americanbankingnews.comZenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 13, 2026 | globenewswire.comSee More Zenas BioPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email. Email Address About Zenas BioPharmaZenas BioPharma (NASDAQ:ZBIO) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns. Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies. Its integrated research infrastructure encompasses medicinal chemistry, in vitro and in vivo pharmacology, as well as manufacturing capabilities to support rapid progression of lead molecules into clinical development. The company’s pipeline includes immuno-oncology candidates designed to modulate checkpoint pathways in solid tumors, alongside antiviral programs targeting broad-spectrum viral threats. Each program is engineered to combine high specificity with favorable pharmacokinetic properties, with key assets currently in IND-enabling stages and early clinical trials. To advance its programs, Zenas BioPharma collaborates with academic institutions and contract research organizations, leveraging external expertise and resources. Serving global markets, the company is committed to addressing unmet medical needs and bringing differentiated therapies to patients worldwide.View Zenas BioPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nasdaq’s 23-Hour Trading Push Could Turn Global Liquidity Into a Growth EngineAnalog Devices’ AI Pivot Could Push Shares to Fresh HighsViking Stock Fell After Earnings, But the Numbers Tell a Different StoryTJX Companies Stock Drop Sets Up Buy Signal as Analysts Stay BullishTarget Is Winning Shoppers Back—Can the Rally Reach $180?Why Lowe’s Could Be a Bargain Before Housing RecoversIs Apple’s AI Strategy Smarter Than Skeptics Think? Upcoming Earnings PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
